Breast Cancer Study of Preoperative Pembrolizumab + Radiation

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 22, 2017

Primary Completion Date

February 6, 2025

Study Completion Date

December 7, 2030

Conditions

Breast Cancer

Interventions

DRUG

Pembrolizumab

checkpoint inhibitor

RADIATION

RT Boost

The second dose of pembrolizumab will be given in conjunction with an RT boost, consisting of 8 Gy for 3 fractions.

Trial Locations (1)

Cedars-Sinai Medical Center, Los Angeles

All Listed Sponsors

collaborator

United States Department of Defense

FED

lead

Stephen Shiao

OTHER

NCT03366844 - Breast Cancer Study of Preoperative Pembrolizumab + Radiation | Biotech Hunter | Biotech Hunter